COMBINATION OF MAPK PATHWAY INHIBITORS AND IMMUNE CHECKPOINT BLOCKADE IN BRAF-MUTANT HIGH-GRADE GLIOMA
Conferences
Park, J-W; Grossauer, S; Wang, W; Daynac, M; Pitteri, S; Monje, M; Grant, G; Petritsch, C
Published in: NEURO-ONCOLOGY
November 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 2021
Volume
23
Start / End Page
172 / 173
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Park, J.-W., Grossauer, S., Wang, W., Daynac, M., Pitteri, S., Monje, M., … Petritsch, C. (2021). COMBINATION OF MAPK PATHWAY INHIBITORS AND IMMUNE CHECKPOINT BLOCKADE IN BRAF-MUTANT HIGH-GRADE GLIOMA. In NEURO-ONCOLOGY (Vol. 23, pp. 172–173).
Park, Jong-Whi, Stefan Grossauer, Wei Wang, Mathieu Daynac, Sharon Pitteri, Michelle Monje, Gerald Grant, and Claudia Petritsch. “COMBINATION OF MAPK PATHWAY INHIBITORS AND IMMUNE CHECKPOINT BLOCKADE IN BRAF-MUTANT HIGH-GRADE GLIOMA.” In NEURO-ONCOLOGY, 23:172–73, 2021.
Park J-W, Grossauer S, Wang W, Daynac M, Pitteri S, Monje M, et al. COMBINATION OF MAPK PATHWAY INHIBITORS AND IMMUNE CHECKPOINT BLOCKADE IN BRAF-MUTANT HIGH-GRADE GLIOMA. In: NEURO-ONCOLOGY. 2021. p. 172–3.
Park, Jong-Whi, et al. “COMBINATION OF MAPK PATHWAY INHIBITORS AND IMMUNE CHECKPOINT BLOCKADE IN BRAF-MUTANT HIGH-GRADE GLIOMA.” NEURO-ONCOLOGY, vol. 23, 2021, pp. 172–73.
Park J-W, Grossauer S, Wang W, Daynac M, Pitteri S, Monje M, Grant G, Petritsch C. COMBINATION OF MAPK PATHWAY INHIBITORS AND IMMUNE CHECKPOINT BLOCKADE IN BRAF-MUTANT HIGH-GRADE GLIOMA. NEURO-ONCOLOGY. 2021. p. 172–173.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 2021
Volume
23
Start / End Page
172 / 173
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis